OVO LABS LIMITED
ActiveKey figures
Like most small UK companies, OVO LABS LIMITED does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.
Ratios
2025/26Sector comparison
SIC 21100Where the company stands among the 1,055 active companies whose first SIC code is 21100 (Manufacture of basic pharmaceutical products).
- GE HEALTHCARE LIMITED£5.6bn
- THERMO FISHER SCIENTIFIC LIFE HOLDINGS LIMITED£1.4bn
- LRC PRODUCTS LIMITED£1bn
- SMITHKLINE BEECHAM LIMITED£940m
- DECHRA LIMITED£780.1m
- IPSEN BIOPHARM LIMITED£588.2m
- ORTHO-CLINICAL DIAGNOSTICS£295.7m
- BESPAK EUROPE LIMITED£256m
- SEQIRUS VACCINES LIMITED£254.2m
- IOVANCE BIOTHERAPEUTICS UK LTD£199.7m
Positions are approximate. Figures come from each company's latest accounts; money and employee figures are compared only with companies that filed accounts in pounds for a period ending in the last two and a half years and are not dormant, so those groups are smaller than 1,055. The line on each bar marks the median.
Summary: OVO LABS LIMITED
What kind of company is it?
OVO LABS LIMITED is a private limited company registered with Companies House under company number 16168449. It was incorporated on 7 Jan 2025. Its status is active. The registered office is in London (SE11). Its nature of business (SIC 2007) is manufacture of basic pharmaceutical products (21100), research and experimental development on biotechnology (72110).
How is the company doing financially?
The latest accounts in the database are for 2025/26 (period ending 31 Jan 2026); the company files micro-entity accounts. Net assets were £3,892,623. Total assets were £3,892,699 and total liabilities £77. The company had an average of 4 employees.
How does it compare with similar companies?
Compared with 1,055 active companies whose first SIC code is 21100: By net assets it ranks higher than 81% of them (median £40,799). By total assets it ranks higher than 74% of them (median £301,666). By number of employees it ranks higher than 73% of them (median 1). It is younger than 86% of them (median age 9.0 years).
Who runs and controls the company?
The company has 4 current directors. 2 persons with significant control are registered.
When are its next filings due?
The next accounts are due by 31 Oct 2027. The next confirmation statement is due by 20 Jan 2027.
Filed accounts2025/26
| 2025/26 | |
|---|---|
| Total assets | 3,892,699 |
| Total liabilities | 77 |
| Net assets / total equity | 3,892,623 |
| Average number of employees | 4 |
A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.
Principal activity
Accounts 2026The principal activity of the company during the year under review was research and experimental development on biotechnology.
As described in the company's latest filed accounts.
History
8 events- Financial year 2025/26 endedAccounts: net assets £3.9m, 4 employees
- James Oliver MACFARLANE appointedDirector
- Melina SCHUH appointedDirector
- Oleksandr YAGENSKY appointedDirector
- Agata Pamela ZIELINSKA appointedDirector
- Dr Melina Schuh registered as a person with significant control
- Dr Agata Pamela Zielinska registered as a person with significant control
- Company incorporatedPrivate limited company
Dates as recorded at Companies House: incorporation, name changes, officer appointments and resignations, current persons with significant control, and the end of each financial year with figures in the database. Former persons with significant control are not listed.